ビオフェルミン製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証1部 | 医薬品 | 4517/E00960 | BIOFERMIN PHARMACEUTICAL CO.,LTD. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2019/08/09 | 日証協 | 37,090株 | +1.64% | 5,100株 | -26.19% | 78,940株 | +3.68% | 6,602株 | +50.01% |
2019/08/02 | 日証協 | 36,490株 | +24.58% | 6,910株 | -34.81% | 76,138株 | +1.74% | 4,401株 | -10.18% |
2019/07/26 | 日証協 | 29,290株 | +34.42% | 10,600株 | +457.89% | 74,837株 | -4.22% | 4,900株 | +133.33% |
2019/07/19 | 日証協 | 21,790株 | +3.32% | 1,900株 | -13.24% | 78,137株 | -3.14% | 2,100株 | -3.14% |
2019/07/12 | 日証協 | 21,090株 | +0.48% | 2,190株 | -50% | 80,669株 | -0.25% | 2,168株 | -42.95% |
2019/07/05 | 日証協 | 20,990株 | +0.91% | 4,380株 | +212.86% | 80,869株 | +0.5% | 3,800株 | +72.73% |
2019/06/28 | 日証協 | 20,800株 | +2.97% | 1,400株 | -76.27% | 80,469株 | -0.25% | 2,200株 | -35.93% |
2019/06/21 | 日証協 | 20,200株 | -7.76% | 5,900株 | +13.46% | 80,669株 | -47.93% | 3,434株 | -31.32% |
2019/06/14 | 日証協 | 21,900株 | +13.47% | 5,200株 | +100% | 154,935株 | -0.58% | 5,000株 | +163.16% |
2019/06/07 | 日証協 | 19,300株 | +6.04% | 2,600株 | +4% | 155,835株 | -3.17% | 1,900株 | -45.71% |
2019/05/31 | 日証協 | 18,200株 | -2.67% | 2,500株 | 0% | 160,935株 | +0.12% | 3,500株 | +600% |
2019/05/24 | 日証協 | 18,700株 | -13.02% | 0株 | -100% | 160,735株 | -0.86% | 500株 | -89.36% |
2019/05/17 | 日証協 | 21,500株 | -12.24% | 1,500株 | -82.14% | 162,130株 | +1.95% | 4,700株 | -96.51% |
2019/05/10 | 日証協 | 24,500株 | +17.79% | 8,400株 | +265.22% | 159,030株 | -2.46% | 134,695株 | +8318.44% |
2019/04/26 | 日証協 | 20,800株 | -16.55% | 2,300株 | -56.6% | 163,035株 | -2.99% | 1,600株 | 0% |
2019/04/19 | 日証協 | 24,925株 | -19.92% | 5,300株 | +8.16% | 168,060株 | -5.67% | 1,600株 | +14.12% |
2019/04/12 | 日証協 | 31,125株 | +0.32% | 4,900株 | -46.74% | 178,158株 | -1.66% | 1,402株 | -61.15% |
2019/04/05 | 日証協 | 31,025株 | +4.37% | 9,200株 | -42.5% | 181,160株 | +2.1% | 3,609株 | -97.74% |
2019/03/29 | 日証協 | 29,725株 | +61.33% | 16,001株 | +283.17% | 177,442株 | +592.27% | 159,718株 | +2239.85% |
※株式分割は考慮していませんのでご注意ください。